A comparative clinical trial of @entity905 , @entity5079 and placebo in XXXX outpatients.

@entity1 @entity308 @entity390 @entity905 @entity5079 @entity353 @entity391 @entity750
@entity905 , a selective @entity750 reuptake inhibitor, was compared with @entity5079 and placebo in a double-blind study. In total, 81 @entity308 @entity1 were included. @entity1 were rated weekly on the @entity308 ( @entity308 ) and the Montgomery _ Asberg Depression Rating Scale (MADRS). The duration was 6 weeks, and 52 @entity1 completed the study. Significantly more @entity1 on @entity905 improved than @entity1 on placebo. For @entity5079 no significant differences were found with either @entity905 or placebo. Mean @entity308 at the end of the study was also statistically significantly lower for @entity905 , but not for @entity5079 , than placebo. Subscores of the MADRS showed improved sleep on @entity5079 at weeks 2 and 3. Suicidal feelings were reduced to a greater degree on @entity905 than on @entity5079 and placebo at weeks 6 and 7. @entity905 induced @entity353 , while @entity1 on @entity5079 gained weight. Side effects were present in most @entity1 on the two active drugs; those on @entity905 experienced @entity390 and @entity391 , and those on @entity5079 drowsiness.
